BRIAN BARASH: Open Payments
NPI 1689663049 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$125,957 in 155 payments from 9 companies in 2025. Trend: 2023 $175,380 · 2024 $155,263 · 2025 $125,957
Speaker / faculty: $73,344Honoraria: $33,300Consulting: $8,858Travel & lodging: $7,404Food & beverage: $3,052
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $33,645 |
| ABBVIE INC. | 33 | $23,598 |
| Supernus Pharmaceuticals, Inc. | 35 | $18,908 |
| Axsome Therapeutics, Inc. | 20 | $14,542 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $14,455 |
| Otsuka America Pharmaceutical, Inc. | 12 | $8,914 |
| Alkermes, Inc. | 6 | $8,280 |
| Tris Pharma Inc | 3 | $3,543 |
| Brainsway USA INC | 1 | $71 |
Products named: UZEDY, VRAYLAR, Qelbree, Auvelity, CAPLYTA, REXULTI, LYBALVI, AUSTEDO XR.
Industry payments across MO — which companies pay providers there.
